Mesothelioma Trial, Recruiting NCT04115254 Sponsor: Dana-Farber Cancer Institute Condition: Mesothelioma
Back to Mesothelioma

Mesothelioma Trial, Recruiting

NCT04115254
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a cancer that your doctor has recommended treating with a precise, targeted form of radiation called stereotactic body radiation therapy (SBRT).
  • Your tumor is no larger than 7 centimeters (about the size of a small apple).
  • You are 18 years of age or older.
  • You are well enough to carry out basic daily activities — your doctor can assess this using a standard health scale (confirm with trial site).
  • You are able to understand and willing to sign a written consent form to participate.
  • There may be additional eligibility requirements depending on where in the body your cancer is located (confirm with trial site).

Who may not be able to join:

  • You have had an allergic reaction to a dye called gadolinium, which is sometimes used during MRI scans (this may not apply if you would not receive the dye — confirm with trial site).
  • You are currently pregnant.
  • You experience severe claustrophobia or anxiety that would make it difficult to be in an enclosed space.
  • You are unable to have an MRI scan for any reason.
  • There may be additional reasons related to where your cancer is located that could affect eligibility (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jonathan Leeman, MD, Brigham and Women's Hospital

Phone: 617-732-6452

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
22 October 2019
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Delivery Success Rate for SMART across multiple tumors-Phase I; Tumor visualization-Phase I; Plan creation-Phase I; Rate of Improvement in Tumor Control-Phase II

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov